Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments of up to $495 million if milestones are met, the Chinese drugmaker said on Tuesday.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs. PFE's dividend is currently covered by cash flow, but payout ratios are stretched, and sustainability is questionable beyond 2027 without new revenue streams. Recent acquisitions, notably Metsera, increase leverage and are dilutive near-term but aim to offset $17–18B annual patent expirations by 2028.
| Pharmaceuticals Industry | Healthcare Sector | Dr. Albert Bourla D.V.M., Ph.D. CEO | CXA Exchange | US7170811035 ISIN |
| BR Country | 81,000 Employees | 6 Mar 2026 Last Dividend | 17 Nov 2020 Last Split | 13 Aug 2012 IPO Date |
Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.